Bendamustine as lymphodepletion for brexucabtagene autoleucel therapy of mantle cell lymphoma.

in Transplantation and cellular therapy by Elise A Chong, Emeline R Chong, Dylan Therwhangher, Sunita D Nasta, Daniel J Landsburg, Stefan K Barta, Jakub Svoboda, James N Gerson, Guido Ghilardi, Luca Paruzzo, Joseph A Fraietta, Elizabeth Weber, Natalie Stefano, David L Porter, Noelle V Frey, Alfred L Garfall, Marco Ruella, Stephen J Schuster

TLDR

  • This study looked at how well patients with a type of cancer called mantle cell lymphoma did when they got a special kind of treatment called brexucabtagene autoleucel (brexu-cel) after a special kind of treatment called lymphodepletion (LD). The study found that the outcomes of patients who got brexu-cel after bendamustine LD were similar to those of patients who got brexu-cel after cy/flu LD. The study also found that CAR T-cell expansion and persistence were observed after bendamustine LD.

Abstract

Brexucabtagene autoleucel (brexu-cel) is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy approved for treatment of relapsed/refractory mantle cell lymphoma (MCL). During a fludarabine shortage, we used bendamustine as an alternative to standard cyclophosphamide/fludarabine (cy/flu) lymphodepletion (LD) prior to brexu-cel. We assessed MCL patient outcomes as well as CAR T-cell expansion and persistence after brexu-cel following bendamustine or cy/flu LD at our center. This was a retrospective single institution study that utilized prospectively banked blood and tissue samples. Clinical efficacy was assessed by 2014 Lugano guidelines. CAR T-cell expansion and persistence in peripheral blood were assessed on day 7 and at ≥month 6 for patients with available samples. Seventeen patients received bendamustine and 5 received cy/flu. For the bendamustine cohort, 14 (82%) received bridging therapy and 4 (24%) had CNS involvement. Fifteen patients (88%) developed CRS with 4 (24%) ≥grade 3 events. Six (35%) patients developed ICANS with 4 (24%) events ≥grade 3. No patient had ≥grade 3 cytopenias at day 90. Best objective (BOR) and complete response (CRR) rates were 82% and 65%, respectively. At 24.5 months median follow-up, 12-month progression-free survival (PFS) was 45%, 24-month PFS was 25%, and median duration of response was 19 months. Median OS was not reached. BOR was 25% (1/4) for patients with CNS involvement. CAR transgene expansion after bendamustine LD was observed on day 7 in all (4/4) patients tested and persisted at ≥6 months (2/2), regardless of response. Bendamustine LD before brexu-cel for MCL is feasible and safe with a lower frequency and shorter duration of cytopenias than reported for cy/flu. Both CAR T-cell expansion and persistence were observed after bendamustine LD. Outcomes appear comparable to the real world outcomes reported with cy/flu LD.

Overview

  • The study assessed the outcomes of patients with relapsed/refractory mantle cell lymphoma (MCL) who received brexucabtagene autoleucel (brexu-cel) after bendamustine or cyclophosphamide/fludarabine (cy/flu) lymphodepletion (LD) at a single institution. The study used prospectively banked blood and tissue samples and assessed clinical efficacy using 2014 Lugano guidelines. CAR T-cell expansion and persistence in peripheral blood were assessed on day 7 and at ≥month 6 for patients with available samples. The primary objective of the study was to compare the outcomes of patients who received brexu-cel after bendamustine or cy/flu LD and determine if bendamustine LD is feasible and safe for MCL patients.

Comparative Analysis & Findings

  • The study found that the outcomes of patients who received brexu-cel after bendamustine LD were comparable to those of patients who received cy/flu LD. The best objective response rate (BOR) was 82% for both groups, and the complete response rate (CRR) was 65% for both groups. The median duration of response was 19 months for both groups. The study also found that CAR T-cell expansion and persistence were observed after bendamustine LD, with CAR transgene expansion observed on day 7 in all (4/4) patients tested and persisting at ≥6 months (2/2), regardless of response.

Implications and Future Directions

  • The study suggests that bendamustine LD before brexu-cel for MCL is feasible and safe with a lower frequency and shorter duration of cytopenias than reported for cy/flu. The study also highlights the importance of CAR T-cell expansion and persistence in MCL patients receiving brexu-cel. Future research could further explore the use of bendamustine LD in MCL patients and compare its outcomes to those of other lymphodepletion regimens.
Read Full Article